HAE Sep 2024 120.000 call
| Previous close | 0.6000 |
| Open | 0.6000 |
| Bid | 0.0000 |
| Ask | 3.2000 |
| Strike | 120.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.6000 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksHaemonetics (HAE) Expands VASCADE Line With New Limited Launch
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
Zacks4 Medical Product Stocks to Buy From a Recovering Industry
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
PR NewswireHaemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.
